ARWR

NEUTRALProduct

Arrowhead Pharmaceuticals, Inc.

2026-08-25

Price

$88.88

+2.48%

This is the 2026-08-25 snapshot — the signals and analysis for ARWR as of this single trading day.

View full ARWR research hub →

Score10.0Top Tier

Signals4/8 DNA2/13 Act · 0/4 Risk

SentimentNEUTRALScore: 8

Volume0.8xvs 20d avg

Analysis

Arrowhead Pharmaceuticals is exhibiting High-Conviction Price Discovery as the market aggressively prices in the upcoming Phase 3 plozasiran data presentation at the August 30 ESC Congress. A highly accommodative RISK_ON macro regime is providing a strong tailwind for biotech risk appetite, amplifying bullish technical signals like the PERFECT_STACK and BOLLINGER_SQUEEZE. Despite recent insider selling noise, institutional absorption—evidenced by fresh 13F accumulation and an analyst upgrade—is driving the stock toward its recent highs, confirming the breakout.

Fired Signals

GOLDEN CROSSBOLLINGER SQUEEZEMARKET LEADERPERFECT STACKSELLER FATIGUESMA BOUNCE

Key Takeaways

Actionable Thesis: Ride the pre-catalyst momentum supported by a Bollinger Squeeze and SMA Bounce, targeting further upside ahead of the imminent ESC Congress data readout.
Key Risk: 'Sell-the-news' dynamics following the August 30 clinical presentation, or underlying friction from recent insider selling near $87.
What to Watch: Maintain a strict trailing stop below the $84.65 support level while monitoring the August 31 investor webcast for forward-looking commercialization insights.

← Back to 2026-08-25 View Full ARWR History →Yahoo Finance &nearr;